[Neonatal group B Streptococcus infection: an integrated approach (of clinical pathologists, gynecologists, midwives, pediatricians-neonatologists) of the functional area of Cuneo (Italy)].
The frequency of early-onset neonatal sepsis without prophylaxis is 1-5/1.000 live births. Since year '70 the most frequent causative microorganism is the group B Streptococcus (S. agalactiae, GBS), followed by Escherichia coli. The mortality rate is now reduced to 4% due to the improvement of neonatal intensive care. In the USA, the incidence of GBS early-onset neonatal sepsis has been markedly reduced by the application of the guidelines released by the Centers for Disease Control (CDC). This strategy, however, is not effective on occurrence of late-onset neonatal group B streptococcal disease. In Italy, the application of CDC guidelines is not customary, and different, often complex, protocols of obstetrical-neonatological integrated approach are applied. The frequency of infectious risk has made the GBS a paramount problem for the neonatologist, even for the legal responsibility issues resulting from the multiplicity of possible options. To reach the best level of protection of the newborn against early-onset GBS infection, the working group of providers of prenatal, obstetric, and neonatal care of the functional area of Cuneo issued an integrated protocol, in order to perform the GBS screening with the optimal culture method suggested by CDC guidelines in the highest possible number of pregnant women, and to standardize the obstetrical and neonatal management.
Terapia Intensiva Neonatale-Neonatologia, 2 Laboratorio Analisi, 3 Ostetricia e Ginecologia-ASO S. Croce e Carle, Cuneo. tin@ospedale.cuneo.it
G
G
Pomero
A
A
Delogu
M
M
Osenda
C
C
Ginardi
P
P
Rattazzi
N
N
Castellino
P
P
Gancia
L
L
Besenzon
R
R
Sardi
G
G
Bricchi
C
C
Vucusa
L
L
Silvestro
M
M
Raggi
P G
PG
Verri
M
M
Toppino
A
A
Serra
M
M
Ardizzoia
S
S
Valle
G
G
Castelli
C
C
Alovisi
M
M
Cardone
G
G
Grazia
G
G
Patrucco
M
M
Nangeroni
L
L
Galletto
D
D
Carpi
D000328:Adult; D000367:Age Factors; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D002985:Clinical Protocols; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D007558:Italy; D008826:Microbial Sensitivity Tests; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis*; D015995:Prevalence; D012007:Rectum / Q000382:microbiology; D012307:Risk Factors; D013290:Streptococcal Infections / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control* / Q000635:transmission; D013292:Streptococcus agalactiae / Q000187:drug effects / Q000302:isolation & purification; D014481:United States; D014621:Vagina / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D004917:Erythromycin